EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Machine Learning–Driven Screening of High‐Activity Antitumor Nanozymes Using an Ensemble Enzymatic Oracle System

Guanmeng Zhang, Mutian Yang, Jie Zang, Xiaoli Li, Qinqiu Zhong, Yuxiang Hu, Yumeng Xie, Ludan Zhang, Yuping Qian, Jinna Ren, Yang Peng, Haitao Chen und 3 weitere

Cancer Nexus · 2025

DOI: 10.1002/cnx2.70005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Nexus, 2025. Verfasst von Guanmeng Zhang und 14 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanozymes, by mimicking the catalytic sites of natural enzymes, have emerged as effective substitutes for traditional natural enzymes. However, the relationship between the physicochemical properties and activity of nanozymes is complex and nonlinear. Traditional laboratory screening and theoretical calculations struggle to handle large‐scale samples and multidimensional parameters, resulting in inefficiency and high costs in the pursuit of high performance nanozymes. Efficiently screening and designing nanozymes with desirable properties remain a significant challenge. Machine learning (ML) technology can capture the complex nonlinear relationship between the physicochemical properties and activity of nanozymes, allowing for the simultaneous processing of multidimensional input variables, thereby achieving more accurate and efficient performance prediction. This study adopts a data‐driven approach to propose an ensemble enzymatic activity prediction model, utilizing ML algorithms to understand the particle–activity relationship, thereby enabling the efficient screening of nanozymes with high peroxidase (POD)‐like activity. The ensemble model integrates five sub‐models, significantly improving prediction accuracy and enhancing generalization compared to single models, achieving an accuracy of 82.4%. External experimental validation results indicate that the model's activity screening outcomes for four nanozymes outside the dataset are consistent with the results of enzymatic activity assays. Further in vitro and in vivo experiments substantiate the effectiveness of the model‐selected nanozymes with POD activity in tumor treatment. This study offers a promising strategy for screening antitumor nanozymes with the desired POD activity and demonstrates the potential of ML in the field of materials science.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, G., Yang, M., Zang, J., Li, X., Zhong, Q., Hu, Y., Xie, Y., Zhang, L., Qian, Y., Ren, J., Peng, Y., Chen, H., Gao, J., Wu, J., & Wang, Y. (2025). Machine Learning–Driven Screening of High‐Activity Antitumor Nanozymes Using an Ensemble Enzymatic Oracle System. Cancer Nexus. https://doi.org/10.1002/cnx2.70005

Vancouver

Zhang G, Yang M, Zang J, Li X, Zhong Q, Hu Y, et al. Machine Learning–Driven Screening of High‐Activity Antitumor Nanozymes Using an Ensemble Enzymatic Oracle System. Cancer Nexus. 2025. doi:10.1002/cnx2.70005

BibTeX
@article{Zhang2025,
  author = {Zhang, Guanmeng and Yang, Mutian and Zang, Jie and Li, Xiaoli and Zhong, Qinqiu and Hu, Yuxiang and Xie, Yumeng and Zhang, Ludan and Qian, Yuping and Ren, Jinna and Peng, Yang and Chen, Haitao and Gao, Jiandong and Wu, Ji and Wang, Yuguang},
  title = {Machine Learning–Driven Screening of High‐Activity Antitumor Nanozymes Using an Ensemble Enzymatic Oracle System},
  journal = {Cancer Nexus},
  year = {2025},
  doi = {10.1002/cnx2.70005}
}
Kostenlos starten →